Clinical Trial Update: A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating YM155 in combination with docetaxel as first-line treatment for HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• YM155 (Sepantronium bromide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED